Top

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Published in:

Open Access 01-12-2023 | Anti-NMDA Receptor Encephalitis | Review

Bortezomib in the management of anti-NMDA receptor encephalitis

Authors: Bryan Gervais de Liyis, Jane Carissa Sutedja, Maria Pramesthi Sabrina Evananda, Ledwin Meikel Wibisono, Chrysanta Paramitha Karuniamaya, Cindy Thiovany Soetomo, Ni Made Susilawathi

Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery | Issue 1/2023

Abstract

Background

Anti-N-methyl d-aspartate (NMDA) receptor encephalitis is an autoimmune encephalitis characterized by neuronal surface antibodies targeting NMDA receptor in the spinal fluid and serum. After acute disseminated encephalomyelitis, anti-NMDA receptor encephalitis is the most frequent cause of autoimmune encephalitis. Despite its clinical significance, the exact prevalence and optimal treatment strategies for this condition remain poorly understood. This comprehensive review aims to evaluate the therapeutic potential of bortezomib as a novel therapy for anti-NMDA receptor encephalitis in hopes of mitigating symptoms and improving outcomes for anti-NMDA receptor encephalitis patients.

Results

The disease is primarily triggered by immunoreactivity against the NMDA receptor 1 (NR1). Recurrence rates are of significant concern in the treatment of anti-NMDA receptor encephalitis, given that a substantial portion of patients are unresponsive to immunosuppressive and immunomodulatory therapies. Thus, the exploration of alternative therapies is necessary. In recent years, bortezomib, a proteasome inhibitor, has emerged as a potential therapeutic candidate by inhibiting autoantibody production against NMDA receptor. Bortezomib exerts immunosuppressive and immunomodulatory effects by inhibiting the production of autoantibodies against NMDA receptor. Studies suggest that bortezomib, by inhibiting proteasome activity and altering antigen presentation, can suppress autoantibody production and immune cell activation, contributing to clinical improvement. However, literature reviews on the utilization of bortezomib in the context of anti-NMDA receptor encephalitis are still highly limited.

Conclusions

Bortezomib presents a promising avenue for intervention. While initial studies suggest its potential to modify the immune response and alleviate symptoms, further comprehensive investigations are imperative to establish optimal dosing, usage guidelines, and long-term safety profiles.

Nosadini M, Granata T, Matricardi S, Freri E, Ragona F, Papetti L, et al. Relapse risk factors in anti-N-methyl-d-aspartate receptor encephalitis. Dev Med Child Neurol. 2019;61:1101–7. https://doi.org/10.1111/dmcn.14267.CrossRefPubMed

Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404. https://doi.org/10.1016/S1474-4422(15)00401-9.CrossRefPubMedPubMedCentral

Dalmau J, Tüzün E, Wu H, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25–36. https://doi.org/10.1002/ana.21050.CrossRefPubMedPubMedCentral

Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10:835–44. https://doi.org/10.1016/S1473-3099(10)70222-X.CrossRefPubMed

Maneta E, Garcia G. Psychiatric manifestations of anti-NMDA receptor encephalitis: neurobiological underpinnings and differential diagnostic implications. Psychosomatics. 2014;55:37–44. https://doi.org/10.1016/j.psym.2013.06.002.CrossRefPubMed

Pollak TA, McCormack R, Peakman M, Nicholson TR, David AS. Prevalence of anti-N-methyl-d-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol Med. 2014;44:2475–87. https://doi.org/10.1017/S003329171300295X.CrossRefPubMed

Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr Res. 2016;176:36–40. https://doi.org/10.1016/j.schres.2014.10.007.CrossRefPubMed

Tsutsui K, Kanbayashi T, Tanaka K, Boku S, Ito W, Tokunaga J, et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry. 2012;12:37. https://doi.org/10.1186/1471-244X-12-37.CrossRefPubMedPubMedCentral

Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–8. https://doi.org/10.1016/S1474-4422(08)70224-2.CrossRefPubMedPubMedCentral

10.

Zhong R, Chen Q, Zhang X, Zhang H, Lin W. Risk factors for mortality in anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis. Front Immunol. 2022;13: 845365. https://doi.org/10.3389/fimmu.2022.845365.CrossRefPubMedPubMedCentral

11.

Li A, Gong X, Guo K, Lin J, Zhou D, Hong Z. Direct economic burden of patients with autoimmune encephalitis in western China. Neurol Neuroimmunol Neuroinflammation. 2020. https://doi.org/10.1212/NXI.0000000000000891.CrossRef

12.

Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother. 2015;15:1391–419. https://doi.org/10.1586/14737175.2015.1115720.CrossRefPubMed

13.

Lejuste F, Thomas L, Picard G, Desestret V, Ducray F, Rogemond V, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflammation. 2016;3: e280. https://doi.org/10.1212/NXI.0000000000000280.CrossRef

14.

Forrester A, Latorre S, O’Dea PK, Robinson C, Goldwaser EL, Trenton A, et al. Anti-NMDAR encephalitis: a multidisciplinary approach to identification of the disorder and management of psychiatric symptoms. Psychosomatics. 2020;61:456–66. https://doi.org/10.1016/j.psym.2020.04.017.CrossRefPubMedPubMedCentral

15.

Samanta D, Lui F. Anti-NMDA receptor encephalitis. Treasure Island: StatPearls; 2023.

16.

Kumar A. NMDA receptor function during senescence: implication on cognitive performance. Front Neurosci. 2015. https://doi.org/10.3389/fnins.2015.00473.CrossRefPubMedPubMedCentral

17.

Adell A. Brain NMDA receptors in schizophrenia and depression. Biomolecules. 2020;10:947. https://doi.org/10.3390/biom10060947.CrossRefPubMedPubMedCentral

18.

Lakhan SE, Caro M, Hadzimichalis N. NMDA receptor activity in neuropsychiatric disorders. Front Psychiatry. 2013;4:52. https://doi.org/10.3389/fpsyt.2013.00052.CrossRefPubMedPubMedCentral

19.

Huang X, Fan C, Wu J, Ye J, Zhan S, Song H, et al. Clinical analysis on anti-N-methyl-d-aspartate receptor encephalitis cases: Chinese experience. Int J Clin Exp Med. 2015;8:18927–35.PubMedPubMedCentral

20.

Wang W, Li J-M, Hu F-Y, Wang R, Hong Z, He L, et al. Anti-NMDA receptor encephalitis: clinical characteristics, predictors of outcome and the knowledge gap in southwest China. Eur J Neurol. 2016;23:621–9. https://doi.org/10.1111/ene.12911.CrossRefPubMed

21.

Huang Q, Xie Y, Hu Z, Tang X. Anti-N-methyl-d-aspartate receptor encephalitis: a review of pathogenic mechanisms, treatment, prognosis. Brain Res. 2020;1727: 146549. https://doi.org/10.1016/j.brainres.2019.146549.CrossRefPubMed

22.

Mann A, Machado NM, Liu N, Mazin A-H, Silver K, Afzal KI. A multidisciplinary approach to the treatment of anti-NMDA-receptor antibody encephalitis: a case and review of the literature. J Neuropsychiatry Clin Neurosci. 2012;24:247–54. https://doi.org/10.1176/appi.neuropsych.11070151.CrossRefPubMed

23.

Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74. https://doi.org/10.1016/S1474-4422(10)70253-2.CrossRefPubMedPubMedCentral

24.

Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65. https://doi.org/10.1016/S1474-4422(12)70310-1.CrossRefPubMedPubMedCentral

25.

Winter O, Dame C, Jundt F, Hiepe F. Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J Immunol. 2012;189:5105–11. https://doi.org/10.4049/jimmunol.1202317.CrossRefPubMed

26.

Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014;13:167–77. https://doi.org/10.1016/S1474-4422(13)70282-5.CrossRefPubMed

27.

Gomes Ferreira M, Lapresa Alcalde V, García Sánchez MH, Hernández Hernández L, Doyague Sánchez MJ. Successful treatment of anti-NMDA receptor encephalitis with early teratoma removal and plasmapheresis: a case report. Medicine (Baltimore). 2018;97: e11325.CrossRefPubMed

28.

Titulaer MJ, Kayser MS, Dalmau J. Prevalence and treatment of anti-NMDA receptor encephalitis—Authors’ reply. Lancet Neurol. 2013;12:425–6. https://doi.org/10.1016/S1474-4422(13)70072-3.CrossRefPubMed

29.

Mohammad SS, Jones H, Hong M, Nosadini M, Sharpe C, Pillai SC, et al. Symptomatic treatment of children with anti-NMDAR encephalitis. Dev Med Child Neurol. 2016;58:376–84. https://doi.org/10.1111/dmcn.12882.CrossRefPubMed

30.

Guang S, Ma J, Ren X, Zhou S, Yang J, Zhang J, et al. Immunotherapies for anti-N-M-methyl-d-aspartate receptor encephalitis: multicenter retrospective pediatric cohort study in China. Front Pediatr. 2021;9: 691599. https://doi.org/10.3389/fped.2021.691599.CrossRefPubMedPubMedCentral

31.

Kolls BJ, O’Keefe YA, Sahgal AK. Autoimmune encephalitis: NMDA receptor encephalitis as an example of translational neuroscience. Neurotherapeutics. 2020;17:404–13. https://doi.org/10.1007/s13311-020-00861-2.CrossRefPubMedPubMedCentral

32.

Turnbull MT, Siegel JL, Becker TL, Stephens AJ, Lopez-Chiriboga AS, Freeman WD. Early bortezomib therapy for refractory anti-NMDA receptor encephalitis. Front Neurol. 2020. https://doi.org/10.3389/fneur.2020.00188.CrossRefPubMedPubMedCentral

33.

Yang J, Liu X. Immunotherapy for refractory autoimmune encephalitis. Front Immunol. 2021. https://doi.org/10.3389/fimmu.2021.790962.CrossRefPubMedPubMedCentral

34.

Nguyen L, Wang C. Anti-NMDA receptor autoimmune encephalitis: diagnosis and management strategies. Int J Gen Med. 2023;16:7–21. https://doi.org/10.2147/IJGM.S397429.CrossRefPubMedPubMedCentral

35.

Sharma A, Preuss CV. Bortezomib. StatPearls: Treasure Island; 2022.

36.

Masaki RI. Mechanism of action of bortezomib in multiple myeloma therapy. Int J Myeloma. 2016;6:1–6.

37.

Damjanov I, Andrews PW. Teratomas produced from human pluripotent stem cells xenografted into immunodeficient mice—a histopathology atlas. Int J Dev Biol. 2016;60:337–419. https://doi.org/10.1387/ijdb.160274id.CrossRefPubMedPubMedCentral

38.

Wu C-Y, Wu J-D, Chen C-C. The association of ovarian teratoma and anti-N-methyl-d-aspartate receptor encephalitis: an updated integrative review. Int J Mol Sci. 2021;22:10911. https://doi.org/10.3390/ijms222010911.CrossRefPubMedPubMedCentral

39.

Dalmau J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: the 2016 cotzias lecture. Neurology. 2016;87:2471–82. https://doi.org/10.1212/WNL.0000000000003414.CrossRefPubMedPubMedCentral

40.

Chefdeville A, Treilleux I, Mayeur M-E, Couillault C, Picard G, Bost C, et al. Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-d-aspartate receptor encephalitis. Acta Neuropathol Commun. 2019;7:38. https://doi.org/10.1186/s40478-019-0693-7.CrossRefPubMedPubMedCentral

41.

Jiang X-Y, Lei S, Zhang L, Liu X, Lin M-T, Blumcke I, et al. Co-expression of NMDA-receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic NMDA-receptor-encephalitis: a retrospective clinico-pathology study of 159 patients. Acta Neuropathol Commun. 2020;8:130. https://doi.org/10.1186/s40478-020-00999-2.CrossRefPubMedPubMedCentral

42.

Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology. 2011;77:589–93. https://doi.org/10.1212/WNL.0b013e318228c136.CrossRefPubMedPubMedCentral

43.

Planagumà J, Haselmann H, Mannara F, Petit-Pedrol M, Grünewald B, Aguilar E, et al. Ephrin-B2 prevents N-methyl-d-aspartate receptor antibody effects on memory and neuroplasticity. Ann Neurol. 2016;80:388–400. https://doi.org/10.1002/ana.24721.CrossRefPubMedPubMedCentral

44.

Mikasova L, De Rossi P, Bouchet D, Georges F, Rogemond V, Didelot A, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012;135:1606–21. https://doi.org/10.1093/brain/aws092.CrossRefPubMed

45.

Deutsch SI, Tang AH, Burket JA, Benson AD. NMDA receptors on the surface of cancer cells: target for chemotherapy? Biomed Pharmacother. 2014;68:493–6. https://doi.org/10.1016/j.biopha.2014.03.012.CrossRefPubMedPubMedCentral

46.

Dale RC, Nosadini M. Infection-triggered autoimmunity: The case of herpes simplex virus type 1 and anti-NMDAR antibodies. Neurol Neuroimmunol Neuroinflammation. 2018;5: e471. https://doi.org/10.1212/NXI.0000000000000471.CrossRef

47.

Garbi N, Kreutzberg T. Dendritic cells enhance the antigen sensitivity of T cells. Front Immunol. 2012;3:389. https://doi.org/10.3389/fimmu.2012.00389.CrossRefPubMedPubMedCentral

48.

Peron JP, Brandão WN, Rossato C, Camara NO. Glutamate ionotropic receptor (NMDAR) modulates T cell survival (IRM7P.712). J Immunol. 2015;194:61.13 LP-61.13.CrossRef

49.

Choi S-C, Morel L. B cell contribution of the CD4(+) T cell inflammatory phenotypes in systemic lupus erythematosus. Autoimmunity. 2017;50:37–41. https://doi.org/10.1080/08916934.2017.1280028.CrossRefPubMedPubMedCentral

50.

Platt MP, Agalliu D, Cutforth T. Hello from the other side: how autoantibodies circumvent the blood-brain barrier in autoimmune encephalitis. Front Immunol. 2017;8:442. https://doi.org/10.3389/fimmu.2017.00442.CrossRefPubMedPubMedCentral

51.

Jézéquel J, Johansson EM, Dupuis JP, Rogemond V, Gréa H, Kellermayer B, et al. Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. Nat Commun. 2017;8:1791. https://doi.org/10.1038/s41467-017-01700-3.CrossRefPubMedPubMedCentral

52.

De Rossi P, Bouchet D, Georges F, Rogemond V, Didelot A, Meissirel C, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012;135:1606–21. https://doi.org/10.1093/brain/aws092.CrossRefPubMed

53.

Huang Y-Q, Xiong H. Anti-NMDA receptor encephalitis: a review of mechanistic studies. Int J Physiol Pathophysiol Pharmacol. 2021;13:1–11.PubMedPubMedCentral

54.

Halliday A, Duncan A, Cheung M, Boston RC, Apiwattanakul M, Camacho X, et al. Second-line immunotherapy and functional outcomes in autoimmune encephalitis: a systematic review and individual patient data meta-analysis. Epilepsia. 2022;63:2214–24. https://doi.org/10.1111/epi.17327.CrossRefPubMedPubMedCentral

55.

Zhang X, Wang C, Zhu W, Wang B, Liang H, Guo S. Factors affecting the response to first-line treatments in patients with anti-N-methyl-d-aspartate receptor encephalitis. J Clin Neurol. 2019;15:369–75. https://doi.org/10.3988/jcn.2019.15.3.369.CrossRefPubMedPubMedCentral

56.

Sakpichaisakul K, Patibat L, Wechapinan T, Sri-Udomkajrorn S, Apiwattanakul M, Suwannachote S. Heterogenous treatment for anti-NMDAR encephalitis in children leads to different outcomes 6–12 months after diagnosis. J Neuroimmunol. 2018;324:119–25. https://doi.org/10.1016/j.jneuroim.2018.09.007.CrossRefPubMed

57.

González Torre JA, Cruz-Gómez ÁJ, Belenguer A, Sanchis-Segura C, Ávila C, Forn C. Hippocampal dysfunction is associated with memory impairment in multiple sclerosis: A volumetric and functional connectivity study. Mult Scler. 2017;23:1854–63. https://doi.org/10.1177/1352458516688349.CrossRefPubMed

58.

Lozada-Martinez ID, Moscote-Salazar L, Quintana Pájaro L, Florez Perdomo WA, Picón Jaimes YA. The use of corticosteroids in autoimmune encephalitis. Basic and clinical considerations. Rom Neurosurg. 2021;35:192–8. https://doi.org/10.33962/roneuro-2021-030.CrossRef

59.

Wang J, Lin J, Wang M, Meng Z, Zhou D, Li J. High dose steroids as first-line treatment increased the risk of in-hospital infections in patients with anti-NMDAR encephalitis. Front Immunol. 2021;12: 774664. https://doi.org/10.3389/fimmu.2021.774664.CrossRefPubMedPubMedCentral

60.

Chi X, Wang W, Huang C, Wu M, Zhang L, Li J, et al. Risk factors for mortality in patients with anti-NMDA receptor encephalitis. Acta Neurol Scand. 2017;136:298–304. https://doi.org/10.1111/ane.12723.CrossRefPubMed

61.

Shin Y-W, Lee S-T, Park K-I, Jung K-H, Jung K-Y, Lee SK, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2018;11:1756285617722347. https://doi.org/10.1177/1756285617722347.CrossRefPubMed

62.

Galeotti C, Kaveri SV, Bayry J. IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol. 2017;29:491–8. https://doi.org/10.1093/intimm/dxx039.CrossRefPubMed

63.

Lee W-J, Lee S-T, Shin Y-W, Lee HS, Shin H-R, Kim D-Y, et al. Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis. Neurother J Am Soc Exp Neurother. 2021;18:474–87. https://doi.org/10.1007/s13311-020-00921-7.CrossRef

64.

Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, et al. Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: a meta-analysis. JAMA Neurol. 2021;78:1333–44. https://doi.org/10.1001/jamaneurol.2021.3188.CrossRefPubMed

65.

Reeves HM, Winters JL. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164:342–51. https://doi.org/10.1111/bjh.12629.CrossRefPubMed

66.

Lu J, Zhang L, Xia C, Tao Y. Complications of therapeutic plasma exchange: a retrospective study of 1201 procedures in 435 children. Medicine (Baltimore). 2019;98: e18308. https://doi.org/10.1097/MD.0000000000018308.CrossRefPubMed

67.

Makuch M, Wilson R, Al-Diwani A, Varley J, Kienzler A-K, Taylor J, et al. N-methyl-D-aspartate receptor antibody production from germinal center reactions: therapeutic implications. Ann Neurol. 2018;83:553–61. https://doi.org/10.1002/ana.25173.CrossRefPubMedPubMedCentral

68.

Hachiya Y, Uruha A, Kasai-Yoshida E, Shimoda K, Satoh-Shirai I, Kumada S, et al. Rituximab ameliorates anti-N-methyl-d-aspartate receptor encephalitis by removal of short-lived plasmablasts. J Neuroimmunol. 2013;265:128–30. https://doi.org/10.1016/j.jneuroim.2013.09.017.CrossRefPubMed

69.

Kong S-S, Chen Y-J, Su I-C, Lin J-J, Chou I-J, Chou M-L, et al. Immunotherapy for anti-NMDA receptor encephalitis: experience from a single center in Taiwan. Pediatr Neonatol. 2019;60:417–22. https://doi.org/10.1016/j.pedneo.2018.10.006.CrossRefPubMed

70.

Tan CRC, Abdul-Majeed S, Cael B, Barta SK. Clinical pharmacokinetics and pharmacodynamics of bortezomib. Clin Pharmacokinet. 2019;58:157–68. https://doi.org/10.1007/s40262-018-0679-9.CrossRefPubMed

71.

Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park). 2004;18:14–21.PubMed

72.

LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res an Off J Am Assoc Cancer Res. 2012;18:2954–63. https://doi.org/10.1158/1078-0432.CCR-11-2873.CrossRef

73.

Fierabracci A. Proteasome inhibitors: a new perspective for treating autoimmune diseases. Curr Drug Targets. 2012;13:1665–75. https://doi.org/10.2174/138945012803530053.CrossRefPubMed

74.

Lazzarin SM, Vabanesi M, Cecchetti G, Fazio R, Fanelli GF, Volonté MA, et al. Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review. J Neurol. 2020;267:2462–8. https://doi.org/10.1007/s00415-020-09988-w.CrossRefPubMed

75.

Scheibe F, Prüss H, Mengel AM, Kohler S, Nümann A, Köhnlein M, et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology. 2017;88:366–70. https://doi.org/10.1212/WNL.0000000000003536.CrossRefPubMed

76.

Foran E, Kwon DY, Nofziger JH, Arnold ES, Hall MD, Fischbeck KH, et al. CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 2016;88:118–24. https://doi.org/10.1016/j.nbd.2016.01.008.CrossRefPubMedPubMedCentral

77.

Caldeira MV, Curcio M, Leal G, Salazar IL, Mele M, Santos ARA, et al. Excitotoxic stimulation downregulates the ubiquitin–proteasome system through activation of NMDA receptors in cultured hippocampal neurons. Biochim Biophys Acta Mol Basis Dis. 2013;1832:263–74. https://doi.org/10.1016/j.bbadis.2012.10.009.CrossRef

78.

Wang T, Wang B, Zeng Z, Li H, Zhang F, Ruan X, et al. Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: an observational study. J Neuroimmunol. 2021;354: 577527. https://doi.org/10.1016/j.jneuroim.2021.577527.CrossRefPubMed

79.

Alé A, Bruna J, Calls A, Karamita M, Haralambous S, Probert L, et al. Inhibition of the neuronal NFκB pathway attenuates bortezomib-induced neuropathy in a mouse model. Neurotoxicology. 2016;55:58–64. https://doi.org/10.1016/j.neuro.2016.05.004.CrossRefPubMed

80.

Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G. Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther. 2015;17:17. https://doi.org/10.1186/s13075-015-0529-1.CrossRefPubMedPubMedCentral

81.

Shin Y-W, Lee S-T, Kim T-J, Jun J-S, Chu K. Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis. Ann Clin Transl Neurol. 2018;5:598–605. https://doi.org/10.1002/acn3.557.CrossRefPubMedPubMedCentral

82.

Kim LN, Edwards L, Goonetilleke N, Kane A, McDougall A, Calic Z. Bortezomib for the treatment of refractory anti-N-methyl-d-aspartate receptor encephalitis. Intern Med J. 2020;50:1591–2. https://doi.org/10.1111/imj.15118.CrossRefPubMed

83.

Sveinsson O, Granqvist M, Forslin Y, Blennow K, Zetterberg H, Piehl F. Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis. J Neuroimmunol. 2017;312:15–8. https://doi.org/10.1016/j.jneuroim.2017.08.011.CrossRefPubMed

84.

Dinoto A, Cheli M, Bratina A, Sartori A, Manganotti P. Bortezomib in anti-N-methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: a systematic review. J Neuroimmunol. 2021;356: 577586. https://doi.org/10.1016/j.jneuroim.2021.577586.CrossRefPubMed

85.

Behrendt V, Krogias C, Reinacher-Schick A, Gold R, Kleiter I. Bortezomib treatment for patients with anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2016;73:1251–3. https://doi.org/10.1001/jamaneurol.2016.2588.CrossRefPubMed

86.

Buske C, Dimopoulos MA, Grunenberg A, Kastritis E, Tomowiak C, Mahé B, et al. Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenström’s Macroglobulinemia: a prospectively randomized trial of the European consortium for Waldenström’s Macroglobulinemia. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41:2607–16. https://doi.org/10.1200/JCO.22.01805.CrossRef

87.

Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38. https://doi.org/10.1016/S1470-2045(15)00464-7.CrossRefPubMed

88.

Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, et al. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma. Blood Cancer J. 2023;13:112. https://doi.org/10.1038/s41408-023-00882-y.CrossRefPubMedPubMedCentral

89.

Lee S-T, Lee HS, Lee W-J, Cha H-A, Kim SH, Shin S-Y, et al. The safety and efficacy of intravenous immunoglobulin in autoimmune encephalitis. Ann Clin Transl Neurol. 2022;9:610–21. https://doi.org/10.1002/acn3.51540.CrossRefPubMedPubMedCentral

90.

Smets I, Titulaer MJ. Antibody therapies in autoimmune encephalitis. Neurotherapeutics. 2022;19:823–31. https://doi.org/10.1007/s13311-021-01178-4.CrossRefPubMedPubMedCentral

91.

Schroeder C, Back C, Koc Ü, Strassburger-Krogias K, Reinacher-Schick A, Gold R, et al. Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis. Clin Neurol Neurosurg. 2018;172:24–6. https://doi.org/10.1016/j.clineuro.2018.06.005.CrossRefPubMed

92.

Cordani R, Micalizzi C, Giacomini T, Gastaldi M, Franciotta D, Fioredda F, et al. Bortezomib responsive refractory anti N methyl d aspartate receptor encephalitis. Pediatr Neurol. 2020;103:61–4. https://doi.org/10.1016/j.pediatrneurol.2019.09.004.CrossRefPubMed

93.

Zhang X-T, Wang C-J, Wang B-J, Guo S-G. The short-term efficacy of combined treatments targeting B cell and plasma cell in severe and refractory Anti-N-methyl-d-aspartate receptor encephalitis: two case reports. CNS Neurosci Ther. 2019;25:151–3. https://doi.org/10.1111/cns.13078.CrossRefPubMed

94.

Keddie S, Crisp SJ, Blackaby J, Cox A, Coles A, Hart M, et al. Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment. Eur J Neurol. 2018;25:1384–8. https://doi.org/10.1111/ene.13759.CrossRefPubMed

95.

Lazzarin SM, Vabanesi M, Cecchetti G, Fazio R, Fanelli GF, Volonté MA, et al. Correction to: Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review. J Neurol. 2021;268:741–2. https://doi.org/10.1007/s00415-020-10370-z.CrossRefPubMed

96.

Simmons ML, Perez KA. Bortezomib for treatment of anti-NMDA receptor encephalitis in a pediatric patient refractory to conventional therapy. Am J Heal Pharm AJHP Off J Am Soc Heal Pharm. 2021;78:395–400. https://doi.org/10.1093/ajhp/zxaa415.CrossRef

Title: Bortezomib in the management of anti-NMDA receptor encephalitis
Authors: Bryan Gervais de Liyis
Jane Carissa Sutedja
Maria Pramesthi Sabrina Evananda
Ledwin Meikel Wibisono
Chrysanta Paramitha Karuniamaya
Cindy Thiovany Soetomo
Ni Made Susilawathi
Publication date: 01-12-2023
Publisher: Springer Berlin Heidelberg
Keywords: Anti-NMDA Receptor Encephalitis
Autoimmune Encephalitis
Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery / Issue 1/2023
Electronic ISSN: 1687-8329
DOI: https://doi.org/10.1186/s41983-023-00765-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Bortezomib in the management of anti-NMDA receptor encephalitis

Abstract

Background

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Risk factors of cognitive impairment post-ischemic stroke

Peripheral visual field defect of vigabatrin in pediatric epilepsy: A review

Epilepsy-associated open-lip schizencephaly with arachnoid cyst: a rare case report

Emerging hallmark of gliomas microenvironment in evading immunity: a basic concept

Author response to "Absence of proximal muscle weakness, dysarthria, and facial diplegia suggest Guillain–Barre syndrome rather than CIDP"

Stroke-related early seizures: clinical and neurophysiological study in a sample of Egyptian population